CRISPR Gene Editing: Medical Miracle or Pandora’s Box?

Podcast: Download
TEC289: CRISPR gene editing is transforming medicine, agriculture, and ethics. Dom Bettinelli, Thomas Sanjurjo, and Jack Baruzzini break down its breakthroughs, risks, and moral questions. Could it cure diseases or lead to designer babies? The future is here!
Get all new episodes automatically and for free:
Follow by Email | Listen to this episode and subscribe on YouTube.
Help us continue to offer Secrets of Technology. Won’t you make a pledge at SQPN.com/give today?
Links for this episode:
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 | TIME
- What are genome editing and CRISPR-Cas9?: MedlinePlus Genetics
- It’s a Gene-Edited Tomato, and It’s Sweet
- ‘Groundbreaking’ Gene-Editing Therapy Receives Ethical Thumbs Up | National Catholic Register
- Correcting Genetic Spelling Errors With Next-Generation CRISPR | WIRED
- When a Lifetime Subscription Can Save You Money—and When It’s Risky
- Nokia is putting the first cellular network on the moon
- Chase will soon block Zelle payments to sellers on social media
- Leave us a review on Apple Podcasts!
- Join the conversation at the StarQuest Facebook page.
- Be part of the StarQuest Discord community at SQPN.com/discord
- Email us feedback or comments to [email protected]
Picks of the Week:
- Jack: LISEN for MagSafe Car Mount
- Thomas: Cardiogram
- Dom: Anker Laptop Power Bank, 25,000mAh
Want to Sponsor A Show?
Support StarQuest’s mission to explore the intersection of faith and pop culture by becoming a named sponsor of the show of your choice on the StarQuest network. Click to get started or find out more.
Disclaimer: Hosts, panelists, and guests may have a financial interest in the companies discussed through investments or other means. Their opinions and recommendations are not affected and do not present a conflict of interest. We offer this statement in the interest of full disclosure.